Submitted by Anonymous (not verified) on 12 October 2026 - 15:35
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Revision: 4, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Revision: 4, Status: Authorised